Cover Image

Anderson-Fabry, the histrionic disease: from genetics to clinical management

Franco Cecchi, Benedetta Tomberli, Amelia Morrone
  • Franco Cecchi
    Department of Clinical and Experimental Medicine, Careggi Hospital, Florence, Italy
  • Benedetta Tomberli
    Department of Clinical and Experimental Medicine; Department of Heart and Vessels, Referral Center for Cardiomyopathies, Careggi Hospital, Florence, Italy |
  • Amelia Morrone
    Department of Neurosciences, Psychology, Pharmacology and Child Health, University of Florence; Molecular and Cell Biology Laboratory, Paediatric Neurology Unit, Neuroscience Department, Meyer Children’s Hospital, Florence, Italy


Anderson-Fabry disease (AFD) is an Xlinked lysosomal storage disorder of glycosphingolipid catabolism, due to deficiency or absence of a galactosidase A (α-gal A) enzyme. The disease may affect males and females, the latter with an average 10 years delay. Metabolites storage (mostly Gb3 and lyso-Gb3) leads to progressive cellular and multiorgan dysfunction, with either early and late onset variable clinical manifestations that usually reduce quality of life and life expectancy. Heart and kidney failure, stroke and sudden death are the most devastating complications. AFD is always been considered a very rare disease, although new epidemiologic data, based on newborn screening, showed that AFD prevalence is probably underestimated and much higher than previously reported, especially for late-onset atypical phenotypes. Currently, the diagnosis may be easier and simpler by evaluating α-gal A enzyme activity and genetic analysis for GLA gene mutations on dried blood spot. While a marked α-gal A deficiency leads to diagnosis of AFD in hemizygous males, the molecular analysis is mandatory in heterozygous females. However, referral to a center with an expert multidisciplinary team is highly advisable, in order to ensure careful management and treatment of patients, based also on accurate molecular and biochemical data interpretation. While long-term efficacy of enzyme replacement therapy (ERT) in advanced stage is still debated, increasing evidence shows greater efficacy of early treatment initiation. Concomitant, organ-specific therapy is also needed. New treatment approaches, such as chemical chaperone therapy, alone or in combination with ERT, are currently under investigation. The present review illustrates the major features of the disease, focusing also on biochemical and genetic aspects.


Anderson-Fabry, heart failure, renal failure, stroke, genetics, enzyme replacement therapy.

Full Text:

Submitted: 2012-11-14 11:08:16
Published: 2013-02-27 09:58:34
Search for citations in Google Scholar
Related articles: Google Scholar
Abstract views:


Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM

Copyright (c) 2013 Franco Cecchi, Benedetta Tomberli, Amelia Morrone

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
© PAGEPress 2008-2018     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185